Literature DB >> 10753531

Curative liver resection for metastatic breast cancer.

S M Maksan1, T Lehnert, G Bastert, C Herfarth.   

Abstract

AIMS: Hepatic resection is a standard procedure in the treatment of colorectal liver metastases. Liver metastases are frequent in breast cancer, but resectional treatment is rarely possible and few reports have addressed the results of surgical treatment for metastatic breast cancer. The aim of our study was to analyse the outcome of patients with metastatic breast cancer after resection of isolated hepatic secondaries and possibly to identify selection criteria for patients who may benefit from surgery.
METHODS: Between 1984 and 1998, 90 patients with a history of breast cancer and suspected liver metastases were referred for surgical evaluation. Fifty-four patients also had extrahepatic disease or metastases from another primary tumour; multiple liver metastases were not amenable to surgical treatment in 20 patients. Five patients were treated by regional chemotherapy via an intra-arterial port catheter; after liver resection two patients were found to have liver metastases from intercurrent colorectal cancer. Thus only nine liver resections for metastatic breast cancer could be performed with curative intent.
RESULTS: No patient died post-operatively after liver resection. In the follow-up period, four of the nine patients who were treated with curative intent received systemic chemotherapy. At a median follow-up of 29 months, four patients died from tumour recurrence. Five patients are currently alive. Five-year survival in the resection group was calculated as 51% (Kaplan-Meier estimate). Node-negative primary breast cancer and a long interval between treatment of the primary and liver metastases appeared to be associated with long survival after liver resection.
CONCLUSIONS: These observations suggest that careful follow-up and adequate patient selection could offer some patients with isolated liver metastases from breast cancer a chance of long-term survival. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10753531     DOI: 10.1053/ejso.1999.0778

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  18 in total

1.  Reported outcome factors for hepatic metastasectomy.

Authors:  N Joseph Espat
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

Review 2.  A role for hepatic surgery in patients with liver metastatic breast cancer: review of literature.

Authors:  Nicolae Bacalbaşa; Sorin Tiberiu Alexandrescu; Irinel Popescu
Journal:  Hepat Oncol       Date:  2015-05-15

Review 3.  Improvement of survival and prospect of cure in patients with metastatic breast cancer.

Authors:  Yee Chung Cheng; Naoto T Ueno
Journal:  Breast Cancer       Date:  2011-05-13       Impact factor: 4.239

Review 4.  The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.

Authors:  Timothy L Fitzgerald; Jason Brinkley; Shannon Banks; Nasreen Vohra; Zachary P Englert; Emmanuel E Zervos
Journal:  Langenbecks Arch Surg       Date:  2014-08-23       Impact factor: 3.445

5.  Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres.

Authors:  Tobias F Jakobs; Ralf-T Hoffmann; Gabriele Poepperl; Anna Schmitz; Jürgen Lutz; Walter Koch; Klaus Tatsch; Andreas Lubiensky; Maximilian F Reiser; Thomas Helmberger
Journal:  Eur Radiol       Date:  2006-12-06       Impact factor: 5.315

6.  Surgical management of breast cancer liver metastases.

Authors:  Maria A Cassera; Chet W Hammill; Michael B Ujiki; Ronald F Wolf; Lee L Swanström; Paul D Hansen
Journal:  HPB (Oxford)       Date:  2011-04       Impact factor: 3.647

7.  Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastasis from breast cancer.

Authors:  D Lawes; A Chopada; A Gillams; W Lees; I Taylor
Journal:  Ann R Coll Surg Engl       Date:  2006-11       Impact factor: 1.891

8.  Is liver resection justified for patients with hepatic metastases from breast cancer?

Authors:  René Adam; Thomas Aloia; Jinane Krissat; Marie-Pierre Bralet; Bernard Paule; Sylvie Giacchetti; Valerie Delvart; Daniel Azoulay; Henri Bismuth; Denis Castaing
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

9.  Liver resection for breast cancer metastasis: does it improve survival?

Authors:  Jean Lubrano; Horace Roman; Sophie Tarrab; Benoit Resch; Loïc Marpeau; Michel Scotté
Journal:  Surg Today       Date:  2008-03-27       Impact factor: 2.549

10.  Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer.

Authors:  Thomas J Vogl; Nagy N N Naguib; Nour-Eldin A Nour-Eldin; Katrin Eichler; Stefan Zangos; Tatjana Gruber-Rouh
Journal:  Eur Radiol       Date:  2009-08-06       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.